Tscan Therapeutics Inc (TCRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tscan Therapeutics Inc (TCRX) has a cash flow conversion efficiency ratio of -0.260x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.00 Million) by net assets ($123.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tscan Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Tscan Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read TCRX current and long-term liabilities for a breakdown of total debt and financial obligations.
Tscan Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tscan Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nh Prime Reit Co Ltd
KO:338100
|
N/A |
|
Spruce Power Holding Corp
NYSE:SPRU
|
-0.027x |
|
Fairvest Ltd
JSE:FTA
|
0.006x |
|
DCC plc
LSE:DCC
|
0.011x |
|
Coffee Day Enterprises Limited
NSE:COFFEEDAY
|
0.025x |
|
PBG S.A
SA:PTBL3
|
0.090x |
|
Essar Shipping Limited
NSE:ESSARSHPNG
|
-0.003x |
|
iFabric Corp
TO:IFA
|
-0.176x |
Annual Cash Flow Conversion Efficiency for Tscan Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Tscan Therapeutics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Tscan Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $123.12 Million | $-135.32 Million | -1.099x | -138.98% |
| 2024-12-31 | $240.97 Million | $-110.82 Million | -0.460x | -13.08% |
| 2023-12-31 | $150.87 Million | $-61.36 Million | -0.407x | +39.19% |
| 2022-12-31 | $99.43 Million | $-66.50 Million | -0.669x | -120.91% |
| 2021-12-31 | $160.78 Million | $-48.68 Million | -0.303x | -525.26% |
| 2020-12-31 | $-42.46 Million | $-3.02 Million | 0.071x | +124.19% |
| 2019-12-31 | $42.54 Million | $-12.52 Million | -0.294x | -- |
About Tscan Therapeutics Inc
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic… Read more